Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie